DRD2 and Parkinson disease: Given their role in the regulation of motor function within the Basal Ganglia, A2A and D2 receptors were evaluated as a Parkinson’s Disease therapeutic target, basing on the results obtained with co-administration of A2A receptor antagonist and L-DOPA or preferential D2R antagonists (Ferré et al., 1997).